GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Global Cord Blood Corp (OTCPK:CORBF) » Definitions » ROE %

Global Cord Blood (Global Cord Blood) ROE %

: 8.69% (As of Mar. 2022)
View and export this data going back to 2007. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Global Cord Blood's annualized net income for the quarter that ended in Mar. 2022 was $66.0 Mil. Global Cord Blood's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $759.3 Mil. Therefore, Global Cord Blood's annualized ROE % for the quarter that ended in Mar. 2022 was 8.69%.

The historical rank and industry rank for Global Cord Blood's ROE % or its related term are showing as below:

CORBF's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -6.24
* Ranked among companies with meaningful ROE % only.

Global Cord Blood ROE % Historical Data

The historical data trend for Global Cord Blood's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Cord Blood Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.88 8.66 12.63 12.73 10.95

Global Cord Blood Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.86 12.35 10.96 11.48 8.69

Competitive Comparison

For the Diagnostics & Research subindustry, Global Cord Blood's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Global Cord Blood ROE % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Global Cord Blood's ROE % distribution charts can be found below:

* The bar in red indicates where Global Cord Blood's ROE % falls into.



Global Cord Blood ROE % Calculation

Global Cord Blood's annualized ROE % for the fiscal year that ended in Mar. 2022 is calculated as

ROE %=Net Income (A: Mar. 2022 )/( (Total Stockholders Equity (A: Mar. 2021 )+Total Stockholders Equity (A: Mar. 2022 ))/ count )
=78.975/( (673.003+769.05)/ 2 )
=78.975/721.0265
=10.95 %

Global Cord Blood's annualized ROE % for the quarter that ended in Mar. 2022 is calculated as

ROE %=Net Income (Q: Mar. 2022 )/( (Total Stockholders Equity (Q: Dec. 2021 )+Total Stockholders Equity (Q: Mar. 2022 ))/ count )
=66.02/( (749.638+769.05)/ 2 )
=66.02/759.344
=8.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2022) net income data. ROE % is displayed in the 30-year financial page.


Global Cord Blood  (OTCPK:CORBF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=66.02/759.344
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(66.02 / 187.376)*(187.376 / 1331.8165)*(1331.8165 / 759.344)
=Net Margin %*Asset Turnover*Equity Multiplier
=35.23 %*0.1407*1.7539
=ROA %*Equity Multiplier
=4.96 %*1.7539
=8.69 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=66.02/759.344
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (66.02 / 88.304) * (88.304 / 89.612) * (89.612 / 187.376) * (187.376 / 1331.8165) * (1331.8165 / 759.344)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7476 * 0.9854 * 47.82 % * 0.1407 * 1.7539
=8.69 %

Note: The net income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Global Cord Blood ROE % Related Terms

Thank you for viewing the detailed overview of Global Cord Blood's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Global Cord Blood (Global Cord Blood) Business Description

Traded in Other Exchanges
N/A
Address
1 Garden Road, 48th Floor, Bank of China Tower, Central, Hong Kong, HKG
Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants.
Executives
Kent C Mccarthy 10 percent owner, other: Mbr 13(d) grp own 10% plus 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Fund Ii Lp 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
7-2010 Grat 5 Under Kent C. Mccarthy Grat Tr Dtd 4-23-2010 other: 13 (d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
7-2010 Grat 6 Under Kent C Mccarthy Grat Tr Dtd 4-23-2010 10 percent owner, other: Member of 13(d) group owning m 7335 COTTONWOOD, SHAWNEE KS 66216
Mccarthy Family Sd, Llc 10 percent owner, other: 13 (d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Fund Ii, Llc other: 13(d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Management Ii, Llc other: 13(d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jcf Co Lf, L.p. other: 13(d) group owning > 10% 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Capital Management Llc other: Member of the group 13021 W 74TH ST, SHAWNEE KS 66216
Jayhawk China Fund Cayman Ltd other: Member of the group 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Gp Ii, L.p. 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
Jayhawk Private Equity, Llc 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205

Global Cord Blood (Global Cord Blood) Headlines

From GuruFocus

Global Cord Blood Corporation Files Annual Report on Form 20-F

By PRNewswire PRNewswire 08-16-2022